Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved by the agency for the acute treatment of migraine.
All News
Advertisement
Advertisement
Advertisement
Baclofen use, particularly at higher doses, may result in an increased risk of encephalopathy among patients with chronic kidney disease.
Officials with the FDA have granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi-Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
4
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
5